Dumping Syndrome Global Market Report 2024

The global dumping syndrome market has grown rapidly in recent years. It will grow from $1.12 billion in 2023 to $1.24 billion in 2024 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period can be attributed to gastric surgery procedures, increased prevalence of obesity, advancements in surgical techniques, improved diagnostic methods.

The global dumping syndrome market is expected to see strong growth in the next few years. It will grow to $1.81 billion in 2028 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to weight loss surgery trends, personalized treatment approaches, nutritional and dietary interventions, telemedicine and remote monitoring. Major trends in the forecast period include minimally invasive surgical techniques, data analytics and ai, increased collaboration, preventive measures.

The increasing prevalence of upper gastrointestinal (GI) diseases is anticipated to be a significant driver for the growth of the dumping syndrome market in the coming years. Upper GI diseases pertain to disorders that affect the upper segment of the digestive system, encompassing the esophagus, stomach, and the initial section of the small intestine (duodenum). Dumping syndrome is a condition that can manifest after individuals undergo specific upper gastrointestinal (GI) surgeries, particularly those involving the stomach, duodenum, or pyloric sphincter. For instance, as of April 2023, the National Library of Medicine reported that upper gastrointestinal bleeding (UGIB) constitutes a prevalent issue, with an estimated incidence rate ranging from 80 to 150 cases per 100,000 individuals annually. Mortality rates are estimated to range from 2 to 15 percent, and UGIB accounts for 75% of all cases of acute gastrointestinal (GI) bleeding. Consequently, the increasing prevalence of upper GI diseases stands as a driving force behind the growth of the dumping syndrome market.

The surge in investment within the healthcare sector is anticipated to be a significant driver for the growth of the dumping syndrome market in the foreseeable future. Healthcare infrastructure encompasses all financial outlays for medical care, preventive measures, public health initiatives, rehabilitation, community health activities, and health research. This heightened healthcare expenditure is pivotal in advancing dumping syndrome treatments, as it enables the development of improved healthcare opportunities, particularly in the realm of dumping syndrome, which necessitates a range of medical diagnoses and treatments. For instance, in May 2023, a report published by The Office for National Statistics revealed that healthcare spending in the UK saw a notable increase of 9.4% in nominal terms and 9.7% in real terms between 2020 and 2021. Moreover, expenditure on preventive care surged to $45.72 billion in 2021, more than doubling from the previous year. Consequently, the escalation in healthcare sector investment is a significant impetus behind the growth of the dumping syndrome market.year. Consequently, the escalation in healthcare.

The presence of treatment-related side effects is expected to exert a limiting influence on the growth of the dumping syndrome market. Dumping syndrome is a condition that can develop after gastric surgery, characterized by the rapid and uncontrolled passage of food and gastric secretions from the stomach into the small intestine. For instance, as of January 2022, Healthline Media LLC reported that medications like octreotide (Sandostatin) or acarbose (Prandase, Precose) have been effective in alleviating the symptoms of dumping syndrome. However, it is important to note that acarbose may lead to side effects such as bloating, diarrhea, and flatulence. Consequently, the presence of treatment-related side effects poses a constraint on the growth of the dumping syndrome market.

Prominent companies in the dumping syndrome market are increasingly prioritizing the introduction of non-invasive tools for gauging gastric emptying, aiming to secure a competitive edge in the industry. Non-invasive methods for assessing gastric emptying involve diagnostic approaches that evaluate the pace at which the stomach releases its contents into the small intestine, without necessitating invasive procedures. For example, in September 2021, Cairn Diagnostics, a US-based life sciences firm, unveiled the 13C-Spirulina Gastric Emptying Breath Test (GEBT). This test entails the consumption of a small portion of Spirulina labeled with a stable carbon isotope, followed by exhalation into a device that quantifies the amount of carbon dioxide in the breath. The rate of carbon dioxide production is then employed to compute the pace of food emptying from the stomach. The GEBT stands as a secure, standardized, and convenient substitute for nuclear medicine-based gastric emptying assessments customarily conducted in nuclear medicine centers. This test can be administered either in a clinical environment or through telehealth services, whether at the patient's residence, offering a non-invasive means to measure gastric emptying velocity and aiding in the diagnosis of gastroparesis.

Leading companies in the dumping syndrome market are embracing cutting-edge technological solutions like the EVIS X1 to bolster their market position. The EVIS X1 endoscopy system introduces three key enhancements expressly crafted to aid healthcare professionals in visualizing gastrointestinal bleeds and anatomical structures. For instance, in April 2020, Olympus Corporation, a renowned Japanese manufacturer of optical and digital technologies, introduced the EVIS X1. This state-of-the-art endoscopy system fosters precise screening and confident diagnosis in the detection, characterization, and management of gastrointestinal issues, encompassing conditions like colorectal cancer (CRC) or bronchial diseases. The system's features encompass advanced imaging techniques like narrow-band imaging (NBI), red dichromatic imaging (RDI), texture and color enhancement imaging (TXI), and extended depth of field (EDOF), collectively enhancing diagnostic capabilities.

Major players in the dumping syndrome market are Cardinal Health Inc., Johnson & Johnson Private Limited, Abbott Laboratories Inc., Medtronic PLC, Covidien PLC, Fujifilm Holdings Corporation, Stryker Corporation, Allergan PLC, Boston Scientific Corporation, B. Braun Melsungen AG, Olympus Corporation, Intuitive Surgical Inc., Terumo Corporation, Steris Corporation, Teleflex Medical Europe Ltd., Cook Medical Inc., Karl Storz SE & Co. KG, Conmed Corporation, Applied Medical Resources Corporation, Richard Wolf GmbH, Pentax Medical Company, GI Dynamics, EndoGastric Solutions Inc., Apollo Endosurgery Inc., EndoChoice Holdings Inc., Cousin Biotech , Mediflex Surgical Product, Asensus Surgical Inc., USGI Medical Inc., TransEnterix Inc.

North America was the largest region in the dumping syndrome market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dumping syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dumping syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of diagnoses for dumping syndrome encompass blood sugar tests, gastric emptying tests, and medical histories, among others. A blood sugar test, also known as a blood glucose test, is a medical examination utilized to gauge the concentration of glucose (sugar) in an individual's bloodstream. Treatment options encompass medication, surgery, and other modalities, which can be administered through various routes like oral, intravenous, and others. These treatments are employed to address different phases of the condition, including both the early and late dumping phases. The services are availed by a range of end-users, including hospitals, clinics, research laboratories, and others.

This report provides dumping syndrome market statistics, including dumping syndrome industry global market size, regional shares, competitors with a dumping syndrome market share, detailed dumping syndrome market segments, market trends and opportunities and any further data you may need to thrive in the dumping syndrome industry. This dumping syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The dumping syndrome market consists of revenues earned by entities by providing endoscopy, surgical interventions and dietary services. The market value includes the value of related goods sold by the service provider or included within the service offering. The dumping syndrome market also includes sales of Acarbose and Octreotide drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.